Abstract
Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Current Bioactive Compounds
Title: Targeting Amoebiasis: Status and Developments
Volume: 3 Issue: 2
Author(s): A. Azam and S. M. Agarwal
Affiliation:
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Abstract: Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Export Options
About this article
Cite this article as:
Azam A. and Agarwal M. S., Targeting Amoebiasis: Status and Developments, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809590
DOI https://dx.doi.org/10.2174/157340707780809590 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Status Epilepticus: An Overview
Current Drug Metabolism Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Current Research on Opioid Receptor Function
Current Drug Targets Clinical and Imaging Findings in the Alveolar Echinococcosis
Current Medical Imaging Glucose Metabolism and Insulin Resistance in Sepsis
Current Pharmaceutical Design Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals